Cancer treatment outcomes vary widely due to inequalities in access to tests, drugs and the need for regular visits to specialist clinics. Many limitations can be addressed by developing more sensitive and robust tests for underexploited cancer biomarkers that can detect cancer sooner, be deployed in local clinics and simplify sample shipment and storage. Such tests will improve health outcomes, and also reduce the substantial environmental impact of biological reagent manufacture and patient travel. MIPrecise is an innovative and integrative network for training of doctoral candidates (DCs) that aims to address these challenges by re-engineering the diagnostic development and delivery pipeline through use of inexpensive, highly stable imprinted polymers. Training a new generation of doctoral scientists in methods that can develop and transition the novel diagnostic and monitoring platforms is crucial, for sustainable development and future impact for cancer patients.

The project is offering 13 PhD positions to work with leading European research groups. The network is funded by the Marie Skłodowska-Curie Horizon Europe programme. 

We are looking for people with solid knowledge in organic, polymer and analytical chemistry, but also in cell biology, as our research is about detecting biomarkers, such as cancer markers in blood and other matrices.